Maynard Um
-
-
-
-
-
-
-
Xencor extends US patent term on Xtend antibodies through 2028
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Xencor, Inc. (XNCR) at Overweight
-
-
-
-
-
-
-
William Blair Starts Xencor, Inc. (XNCR) at Outperform
-
-
-
-
-
-
-
Xencor (XNCR) Presents Preclinical Data on XmAb942
-
-
-
-
-
-
-
Barclays Reiterates Underweight Rating on Xencor, Inc. (XNCR), PT $22, Shares Gain ~24% Today
-
-
-
-
-
-
404,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

